XHKG
1789
Market cap647mUSD
Oct 09, Last price
4.67HKD
1D
-1.48%
1Q
-11.05%
IPO
74.91%
Name
AK Medical Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehensive product offerings encompass conventional knee, hip, and spine replacement implants, as well as advanced 3D-printed solutions like hip implants, artificial vertebral bodies, and spinal interbody cages. The company further expands its operations by distributing orthopedic products from third-party manufacturers and by fabricating surgical instruments and medical irrigators. Its diverse client base spans distributors, hospitals, physicians, surgeons, and directly serves patients. Established in Beijing, People's Republic of China, in 2003, AK Medical Holdings Limited functions as a subsidiary of Ximalaya Limited.
Key people
Zhijiang Li
Executive Chairman of the Board, Chief Executive Officer · since 2016
Kun Liang
Chief Financial Officer · since 2020
Bin Zhang
Senior Vice President, Executive Director · since 2016
Aiguo Liu
Vice President, Head of the Compliance and Quality Management Committee of AK Medical, General Manager of ITI Medical Co., Ltd · since 2024
Chaoyang Zhang
Senior Vice President, Executive Director · since 2016
Xiaohong Zhao
Executive Director · since 2020
Hanzhong Sun
Vice President of Human Resources of AK Medical Group · since 2021
Caimei Wang
Chief Technology Officer of AK Medical Group, Director of AK Medical Beijing Research Center · since 2024
Rongkun Ma
Company Secretary · since 2024
Non-Executive Director · since 2016
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2017
Shu Wing Li
Non-Executive Independent Director · since 2017
IPO date
Dec 20, 2017
Employees
1,082
Domiciled in
CN
Incorporated in
KY
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||